Drugs / RHEZ
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT05221502 Comparator | Apr 2022 → Apr 2024 | pulmonary tuberculosis | Otsuka Pharmaceutical Development & Commercialization, Inc. | Completed | Met primary |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RHEZ | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05221502 ↗ |
| Route | Oral | “All drugs were administered orally.” PMID 42214407 ↗ May 2026 |